Cargando…
Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials
Background: Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of psoriasis with considerable benefits and a low toxicity. The purpose of this quantitative study was to show high-quality evidence of the efficacy and safety of CHM for the treatment of psoriasis to promote it...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862748/ https://www.ncbi.nlm.nih.gov/pubmed/33551804 http://dx.doi.org/10.3389/fphar.2020.599433 |
_version_ | 1783647356593373184 |
---|---|
author | Luo, Yue Chen, Jiale Kuai, Le Zhang, Ying Ding, Xiaojie Luo, Ying Ru, Yi Xing, Meng Li, Hongjin Sun, Xiaoying Li, Bin Li, Xin |
author_facet | Luo, Yue Chen, Jiale Kuai, Le Zhang, Ying Ding, Xiaojie Luo, Ying Ru, Yi Xing, Meng Li, Hongjin Sun, Xiaoying Li, Bin Li, Xin |
author_sort | Luo, Yue |
collection | PubMed |
description | Background: Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of psoriasis with considerable benefits and a low toxicity. The purpose of this quantitative study was to show high-quality evidence of the efficacy and safety of CHM for the treatment of psoriasis to promote its clinical application. Methods: Several databases were systematically searched including PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, Chinese Scientific Journals Database, and Wan Fang Database. High-quality randomized controlled trials that compared CHM with non-CHM interventions were included. The RevMan5.3 software was used to calculate risk ratios (RR) at 95% confidence intervals (CI) and conduct the meta-analysis. Results: Altogether, 1,215 patients participated in this study, including 711 in the experimental group and 504 in the control group. The psoriasis area severity index (PASI) score of the CHM group was significantly lower than that of the placebo group (MD, −4.02; 95% CI, −6.71 to −1.34; p = 0.003). To achieve PASI-60 and PASI-75, the arrival rate of the CHM group was higher than that of the placebo group (PASI-60: RR, 3.52; 95% CI, 1.17 to 10.61; p = 0.03; PASI-75: RR, 9.87; 95% CI, 3.11 to 31.31; p = 0.0001). Furthermore, the efficacy rate was higher in patients receiving CHM than in those receiving placebo (RR, 1.72; 95% CI, 1.01 to 2.93; p = 0.04). The results suggested a greater impact of CHM in improving the dermatology life quality index (DLQI) of patients (MD, −2.12; 95% CI, −3.75 to −0.49; p = 0.01). Regarding pruritus severity, there was no significant difference between the two groups (MD, −1.90; 95% CI, −3.79 to −0.01; p = 0.05). The meta-analysis revealed that the recurrence rate (RR, 0.74; 95% CI, 0.32 to 1.71; p = 0.48) and proportion of adverse events (RR, 1.36; 95% CI, 0.95 to 1.93; p = 0.09) associated with using CHM were similar to those associated with using a placebo. Conclusion: CHM appears safe and effective in the treatment of psoriasis and has a great positive impact on the DQLI of patients; however, CHM could not completely eliminate skin lesions, improve pruritus severity, and reduce the recurrence rate. |
format | Online Article Text |
id | pubmed-7862748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78627482021-02-06 Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials Luo, Yue Chen, Jiale Kuai, Le Zhang, Ying Ding, Xiaojie Luo, Ying Ru, Yi Xing, Meng Li, Hongjin Sun, Xiaoying Li, Bin Li, Xin Front Pharmacol Pharmacology Background: Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of psoriasis with considerable benefits and a low toxicity. The purpose of this quantitative study was to show high-quality evidence of the efficacy and safety of CHM for the treatment of psoriasis to promote its clinical application. Methods: Several databases were systematically searched including PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, Chinese Scientific Journals Database, and Wan Fang Database. High-quality randomized controlled trials that compared CHM with non-CHM interventions were included. The RevMan5.3 software was used to calculate risk ratios (RR) at 95% confidence intervals (CI) and conduct the meta-analysis. Results: Altogether, 1,215 patients participated in this study, including 711 in the experimental group and 504 in the control group. The psoriasis area severity index (PASI) score of the CHM group was significantly lower than that of the placebo group (MD, −4.02; 95% CI, −6.71 to −1.34; p = 0.003). To achieve PASI-60 and PASI-75, the arrival rate of the CHM group was higher than that of the placebo group (PASI-60: RR, 3.52; 95% CI, 1.17 to 10.61; p = 0.03; PASI-75: RR, 9.87; 95% CI, 3.11 to 31.31; p = 0.0001). Furthermore, the efficacy rate was higher in patients receiving CHM than in those receiving placebo (RR, 1.72; 95% CI, 1.01 to 2.93; p = 0.04). The results suggested a greater impact of CHM in improving the dermatology life quality index (DLQI) of patients (MD, −2.12; 95% CI, −3.75 to −0.49; p = 0.01). Regarding pruritus severity, there was no significant difference between the two groups (MD, −1.90; 95% CI, −3.79 to −0.01; p = 0.05). The meta-analysis revealed that the recurrence rate (RR, 0.74; 95% CI, 0.32 to 1.71; p = 0.48) and proportion of adverse events (RR, 1.36; 95% CI, 0.95 to 1.93; p = 0.09) associated with using CHM were similar to those associated with using a placebo. Conclusion: CHM appears safe and effective in the treatment of psoriasis and has a great positive impact on the DQLI of patients; however, CHM could not completely eliminate skin lesions, improve pruritus severity, and reduce the recurrence rate. Frontiers Media S.A. 2021-01-22 /pmc/articles/PMC7862748/ /pubmed/33551804 http://dx.doi.org/10.3389/fphar.2020.599433 Text en Copyright © 2021 Luo, Chen, Kuai, Zhang, Ding, Luo, Ru, Xing, Li, Sun, Li and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Luo, Yue Chen, Jiale Kuai, Le Zhang, Ying Ding, Xiaojie Luo, Ying Ru, Yi Xing, Meng Li, Hongjin Sun, Xiaoying Li, Bin Li, Xin Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title | Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title_full | Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title_fullStr | Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title_full_unstemmed | Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title_short | Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials |
title_sort | chinese herbal medicine for psoriasis: evidence from 11 high-quality randomized controlled trials |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862748/ https://www.ncbi.nlm.nih.gov/pubmed/33551804 http://dx.doi.org/10.3389/fphar.2020.599433 |
work_keys_str_mv | AT luoyue chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT chenjiale chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT kuaile chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT zhangying chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT dingxiaojie chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT luoying chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT ruyi chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT xingmeng chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT lihongjin chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT sunxiaoying chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT libin chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials AT lixin chineseherbalmedicineforpsoriasisevidencefrom11highqualityrandomizedcontrolledtrials |